GlassScriptPhysician profile
Shayla Ebersold
NPI 1740845213
$1,317.06
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $99.64 · 2023: $152 · 2024: $509 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.32 |
| Education | $215.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $129.71 | 2024 | Alecensa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.56 | 2024 | Lynparza, Enhertu |
| Lilly USA, LLC | $115.76 | 2024 | Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $115.57 | 2021 | |
| Gilead Sciences, INC. | $111.53 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $101.34 | 2024 | Ojjaara |
| Jazz Pharmaceuticals INC. | $99.64 | 2022 | |
| Amgen INC. | $87.83 | 2025 | Imdelltra (Amg757) |
| Puma Biotechnology, INC. | $77.71 | 2023 | |
| Emd Serono, INC. | $74.41 | 2023 | Bavencio |
| Coherus Oncology, INC. | $65.78 | 2021 | |
| Geron Corporation | $50.44 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $24.38 | 2024 | Keytruda |
| Eisai INC. | $15.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayla Ebersold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.